In this article, we present the pivotal abstracts presented at the ‘AACR Virtual Meeting: COVID-19 and Cancer’ held in July 2020. Much is unknown regarding the effect of COVID-19 on cancer patients, and this conference presented important updates in therapeutics and epidemiology. Specifically, cancer therapeutics have been hypothesized to treat cytokine release syndrome in patients with COVID-19, and the JAK1/2 inhibitor, ruxolitinib, is currently being used in a Phase III trial to assess its efficacy. Additionally, similar to other studies, morbidity and mortality in patients with COVID-19 and cancer appear to be worse in older patients and in males. We also present various COVID-19 data related to breast cancer, lung cancer, hematologic malignancies, melanoma and prostate cancer.
【저자키워드】 COVID-19, Vaccine, Cancer, Cytokine release syndrome, oncology, 【초록키워드】 Efficacy, Breast cancer, Trial, Epidemiology, lung cancer, older patient, Cancer patients, Melanoma, Prostate cancer, ruxolitinib, morbidity and mortality, inhibitor, phase, Abstract, treat, malignancies, hematologic, males, patients with COVID-19,